Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection

Henna Kekki, Mari Peltola, Sandra van Vliet, Chris Bangma, Yvette van Kooyk, Kim Pettersson

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

OBJECTIVES: The objective was to study the differences in PSA fucosylation obtained from LNCaP and PC-3 prostate cancer cell lines, seminal plasma PSA and recombinant precursor form of PSA expressed in baculovirus, using Aleuria aurantia lectin (AAL). The aim was to assess whether differences in fucosylation (Fucα1-6/3GlcNAc carbohydrates) of PSA either in urine, blood or tissue enable the discrimination of patients with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) and young males.

DESIGN AND METHODS: Two novel lectin-immunoassays were developed for the analysis of fucosylation of PSA by measuring the time-resolved fluorescence of europium chelate. The lectin-immunoassays utilize free PSA-specific Fab-fragments for capturing the analyte and either europium-labeled AAL or AAL coupled to Eu(III)-chelate-dyed nanoparticles for the detection of Fucα1-6/3GlcNAc carbohydrates on PSA.

RESULTS: Using the novel lectin-immunoassays, we showed higher levels of Fucα1-6/3GlcNAc on PSA derived from LNCaP and PC-3 cells compared to seminal plasma PSA. With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.

CONCLUSIONS: AAL coupled to Eu(III)-chelate-dyed nanoparticles improved the sensitivity of immunoassay for the detection of Fucα1-6/3GlcNAc structures on PSA. The preliminary findings show an increased fucosylation in PCa compared to benign conditions. Further validation is required to assess the true clinical utility of AAL in PCa diagnosis.

Original languageEnglish
Pages (from-to)54-61
Number of pages8
JournalClinical Biochemistry
Volume50
Issue number1-2
DOIs
Publication statusPublished - Jan 2017

Cite this

@article{0005cdded7f64434ad9bf5c691601d85,
title = "Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection",
abstract = "OBJECTIVES: The objective was to study the differences in PSA fucosylation obtained from LNCaP and PC-3 prostate cancer cell lines, seminal plasma PSA and recombinant precursor form of PSA expressed in baculovirus, using Aleuria aurantia lectin (AAL). The aim was to assess whether differences in fucosylation (Fucα1-6/3GlcNAc carbohydrates) of PSA either in urine, blood or tissue enable the discrimination of patients with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) and young males.DESIGN AND METHODS: Two novel lectin-immunoassays were developed for the analysis of fucosylation of PSA by measuring the time-resolved fluorescence of europium chelate. The lectin-immunoassays utilize free PSA-specific Fab-fragments for capturing the analyte and either europium-labeled AAL or AAL coupled to Eu(III)-chelate-dyed nanoparticles for the detection of Fucα1-6/3GlcNAc carbohydrates on PSA.RESULTS: Using the novel lectin-immunoassays, we showed higher levels of Fucα1-6/3GlcNAc on PSA derived from LNCaP and PC-3 cells compared to seminal plasma PSA. With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.CONCLUSIONS: AAL coupled to Eu(III)-chelate-dyed nanoparticles improved the sensitivity of immunoassay for the detection of Fucα1-6/3GlcNAc structures on PSA. The preliminary findings show an increased fucosylation in PCa compared to benign conditions. Further validation is required to assess the true clinical utility of AAL in PCa diagnosis.",
keywords = "Cell Line, Tumor, Europium, Humans, Lectins, Male, Metal Nanoparticles, Prostate-Specific Antigen, Prostatic Neoplasms, Sensitivity and Specificity, Journal Article",
author = "Henna Kekki and Mari Peltola and {van Vliet}, Sandra and Chris Bangma and {van Kooyk}, Yvette and Kim Pettersson",
note = "Copyright {\circledC} 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.",
year = "2017",
month = "1",
doi = "10.1016/j.clinbiochem.2016.06.015",
language = "English",
volume = "50",
pages = "54--61",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "1-2",

}

Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection. / Kekki, Henna; Peltola, Mari; van Vliet, Sandra; Bangma, Chris; van Kooyk, Yvette; Pettersson, Kim.

In: Clinical Biochemistry, Vol. 50, No. 1-2, 01.2017, p. 54-61.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Improved cancer specificity in PSA assay using Aleuria aurantia lectin coated Eu-nanoparticles for detection

AU - Kekki, Henna

AU - Peltola, Mari

AU - van Vliet, Sandra

AU - Bangma, Chris

AU - van Kooyk, Yvette

AU - Pettersson, Kim

N1 - Copyright © 2016 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

PY - 2017/1

Y1 - 2017/1

N2 - OBJECTIVES: The objective was to study the differences in PSA fucosylation obtained from LNCaP and PC-3 prostate cancer cell lines, seminal plasma PSA and recombinant precursor form of PSA expressed in baculovirus, using Aleuria aurantia lectin (AAL). The aim was to assess whether differences in fucosylation (Fucα1-6/3GlcNAc carbohydrates) of PSA either in urine, blood or tissue enable the discrimination of patients with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) and young males.DESIGN AND METHODS: Two novel lectin-immunoassays were developed for the analysis of fucosylation of PSA by measuring the time-resolved fluorescence of europium chelate. The lectin-immunoassays utilize free PSA-specific Fab-fragments for capturing the analyte and either europium-labeled AAL or AAL coupled to Eu(III)-chelate-dyed nanoparticles for the detection of Fucα1-6/3GlcNAc carbohydrates on PSA.RESULTS: Using the novel lectin-immunoassays, we showed higher levels of Fucα1-6/3GlcNAc on PSA derived from LNCaP and PC-3 cells compared to seminal plasma PSA. With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.CONCLUSIONS: AAL coupled to Eu(III)-chelate-dyed nanoparticles improved the sensitivity of immunoassay for the detection of Fucα1-6/3GlcNAc structures on PSA. The preliminary findings show an increased fucosylation in PCa compared to benign conditions. Further validation is required to assess the true clinical utility of AAL in PCa diagnosis.

AB - OBJECTIVES: The objective was to study the differences in PSA fucosylation obtained from LNCaP and PC-3 prostate cancer cell lines, seminal plasma PSA and recombinant precursor form of PSA expressed in baculovirus, using Aleuria aurantia lectin (AAL). The aim was to assess whether differences in fucosylation (Fucα1-6/3GlcNAc carbohydrates) of PSA either in urine, blood or tissue enable the discrimination of patients with prostate cancer (PCa) from benign prostatic hyperplasia (BPH) and young males.DESIGN AND METHODS: Two novel lectin-immunoassays were developed for the analysis of fucosylation of PSA by measuring the time-resolved fluorescence of europium chelate. The lectin-immunoassays utilize free PSA-specific Fab-fragments for capturing the analyte and either europium-labeled AAL or AAL coupled to Eu(III)-chelate-dyed nanoparticles for the detection of Fucα1-6/3GlcNAc carbohydrates on PSA.RESULTS: Using the novel lectin-immunoassays, we showed higher levels of Fucα1-6/3GlcNAc on PSA derived from LNCaP and PC-3 cells compared to seminal plasma PSA. With the more sensitive nanoparticle-based lectin-immunoassay we detected a statistically significant increase in the PSA fucosylation in PCa tissue compared to benign tissue (p=0.001) and in urine from PCa patients compared to BPH patients (p=0.030), and an even greater discrimination (p=0.010) when comparing BPH patients to PCa patients with Gleason score≥7.CONCLUSIONS: AAL coupled to Eu(III)-chelate-dyed nanoparticles improved the sensitivity of immunoassay for the detection of Fucα1-6/3GlcNAc structures on PSA. The preliminary findings show an increased fucosylation in PCa compared to benign conditions. Further validation is required to assess the true clinical utility of AAL in PCa diagnosis.

KW - Cell Line, Tumor

KW - Europium

KW - Humans

KW - Lectins

KW - Male

KW - Metal Nanoparticles

KW - Prostate-Specific Antigen

KW - Prostatic Neoplasms

KW - Sensitivity and Specificity

KW - Journal Article

U2 - 10.1016/j.clinbiochem.2016.06.015

DO - 10.1016/j.clinbiochem.2016.06.015

M3 - Article

VL - 50

SP - 54

EP - 61

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 1-2

ER -